Current role of gemcitabine in the treatment of Hodgkin lymphoma. - Wikidata - awgldk - TriplyDB

Current role of gemcitabine in the treatment of Hodgkin lymphoma.

Current role of gemcitabine in the treatment of Hodgkin lymphoma.

http://www.wikidata.org/entity/Q37152761

about

Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.

P2860

Q34575857-37577E6C-659B-40D8-8428-4030C308FD60 Q40075321-9860F790-45F3-4EEE-87FD-3FAAE3131DD4

P2860

Current role of gemcitabine in the treatment of Hodgkin lymphoma.

http://www.wikidata.org/entity/Q37152761

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Current role of gemcitabine in the treatment of Hodgkin lymphoma.

@en

Current role of gemcitabine in the treatment of Hodgkin lymphoma.

@nl

type

label

Current role of gemcitabine in the treatment of Hodgkin lymphoma.

@en

Current role of gemcitabine in the treatment of Hodgkin lymphoma.

@nl

prefLabel

Current role of gemcitabine in the treatment of Hodgkin lymphoma.

@en

Current role of gemcitabine in the treatment of Hodgkin lymphoma.

@nl

P1433

Q37152761-9049A768-E778-49CA-81B5-5FC1F4A08DD4

P1476

Q37152761-93104713-909E-451A-B2FB-ECF6CD7D063C

P2093

Q37152761-6D91123C-8A60-4BA2-9E0E-2C13E8C4603A

Q37152761-A5D84A65-A811-4A44-9625-12E946EA0D9B

P2860

Q37152761-014A0206-38EF-4710-B195-93134623CB73

Q37152761-105A3022-EAEE-46F1-8202-CEC5BE3B26FD

Q37152761-147D5FD1-93B3-4F61-B9D8-F1A519FBAAC1

Q37152761-1ED277E6-D6BD-40EB-B13E-CEC2947A3867

Q37152761-21247BF1-AC93-4A1C-8A79-DFC12F89EA75

Q37152761-36FDE14A-F3E2-4F04-8CB9-8172F947D768

Q37152761-44D663B1-34A6-4577-BBF4-7D31F6C397D1

Q37152761-59CC0C3C-9460-43B5-8B21-12A2A503BBC8

Q37152761-612F613C-D08A-4802-BEBE-57B83C4BCCC3

Q37152761-63AE23F7-3FD5-4FD7-926E-E1E4149D9821

P304

Q37152761-442A9010-9136-4850-AD3A-C9EF14962206

P31

Q37152761-91EF9302-BB47-41DD-AD59-53A2A5AA248D

P356

Q37152761-EEA6D6E5-05F4-4FE8-ABD0-7FB488316D03

P433

Q37152761-832872A7-CAF4-490F-A5FF-97FCB23ADC8D

P478

Q37152761-19FF2DCA-8FDF-423E-86EB-E215B094BE09

P577

Q37152761-FF648E6D-44F5-47E0-B292-50C4AD5BF2EC

P698

Q37152761-22F0978F-897C-452B-BFE4-74BAA3852780

P356

10428190801911704

P1433

Leukemia & Lymphoma

P1476

Current role of gemcitabine in the treatment of Hodgkin lymphoma.

@en

P2093

Anas Younes

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Oki

http://www.w3.org/2001/XMLSchema#string

P2860

Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.

Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma.

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.

Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.

ESHAP is an active regimen for relapsing Hodgkin's disease.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.

P304

883-889

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428190801911704

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18452104

http://www.w3.org/2001/XMLSchema#string